The Ambidextrous Medical Device Industry
With the public markets for now all but closed to them, small, private medical device firms are forced to turn to a number of new financing and business models. There will be no public-market support unless the companies can live up to sales and earnings projections. The historic split between small companies as innovators and big companies as disseminators of new technology has shifted slightly in the wake of the new financing environment, resulting in an imbalance favoring big companies.
You may also be interested in...
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
European Commission medtech news all but dried up in September. But the UK’s Brexit news and implications for medtech has given EU and UK medtech stakeholders enough to ponder.
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.